ID   BT474-J4
AC   CVCL_ZL46
SY   BT-474-J4
DR   cancercelllines; CVCL_ZL46
DR   GEO; GSM799174
DR   GEO; GSM799175
DR   GEO; GSM799176
DR   GEO; GSM799177
DR   GEO; GSM799178
DR   GEO; GSM799179
DR   GEO; GSM799180
DR   GEO; GSM799181
DR   GEO; GSM799182
DR   GEO; GSM799183
DR   GEO; GSM799184
DR   GEO; GSM799185
DR   Wikidata; Q98125591
RX   PubMed=19671800;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Tyverb).
CC   Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (PubMed=19671800).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=19671800).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0179 ! BT-474
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=19671800; DOI=10.1158/0008-5472.CAN-08-4490;
RA   Liu L., Greger J.G., Shi H., Liu Y., Greshock J., Annan R., Halsey W.,
RA   Sathe G.M., Martin A.-M., Gilmer T.M.;
RT   "Novel mechanism of lapatinib resistance in HER2-positive breast tumor
RT   cells: activation of AXL.";
RL   Cancer Res. 69:6871-6878(2009).
//